Cited by 319Peroxisome Proliferator-Activated ReceptorsNeuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatments

The DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index.

PPARs in the brain

HENEKA, M, LANDRETH, G·2007·Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids

DOI 10.1016/j.bbalip.2007.04.016

Open this paper in CoChat — free account

Abstract

The biology of peroxisome proliferator activated receptors (PPARs) in physiological and pathophysiological processes has been primarily studied in peripherial organs and tissues. Recently it became clear that PPARs play an important role for the pathogenesis of various disorders of the CNS. The finding that activation of PPARs, and in particular, the PPARgamma isoform, suppresses inflammation in peripherial macrophages and in models of human autoimmune disease, instigated the experimental evaluation of these salutary actions for several CNS disorders that have an inflammatory component. Activation of all PPAR isoforms, but especially of PPARgamma, has been found to be protective in murine in vitro and in vivo models of Multiple Sclerosis. The verification of these findings in human cells prompted the initiation of clinical studies evaluating PPARgamma activation in Multiple Sclerosis patients. Likewise, Alzheimer's disease has a prominent inflammatory component that arises in response to neurodegeneration and to extracellular deposition of beta-amyloid peptides. The fact that non steroidal anti-inflammatory drugs (NSAIDs) delay the onset and reduce the risk to develop Alzheimer's disease, while they also bind to and activate PPARgamma, led to the hypothesis that one dimension of NSAID protection in AD may be mediated by PPARgamma. Several lines of evidence from in vitro and in vivo studies have supported this hypothesis, using Alzheimer disease related transgenic cellular and…

Integrity signals

Registry

Crossref · 10.1016/j.bbalip.2007.04.016

Cites

181 of 181 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,675
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism
Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,115
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
The many roles of chemokines and chemokine receptors in inflammation
Charo, I. F., & Ransohoff, R. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052723 · Cited by 2,523
World Cancer Report
Stewart, B. W., & Kleihues, P. (2003) · Cited by 2,389
Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development
Barak, Y., Nelson, M. C., Ong, E. S., Jones, Y., Ruiz‐Lozano, P., Chien, K. R., Koder, A., & Evans, R. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80209-9 · Cited by 1,983

Show all 181 references

Sorted by citations

Alzheimer's disease: strategies for disease modification
Citron, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2896 · Cited by 1,075
The Peroxisome Proliferator-Activated Receptor: A Family of Nuclear Receptors Role in Various Diseases
Tyagi, S., Gupta, P., Saini, A., Kaushal, C., & Sharma, S. (2011) · Journal of Advanced Pharmaceutical Technology & Research · doi:10.4103/2231-4040.90879 · Cited by 1,017
Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications
Pajares, M., I. Rojo, A., Manda, G., Boscá, L., & Cuadrado, A. (2020) · Cells · doi:10.3390/cells9071687 · Cited by 779
Lipid Oxidation and Peroxidation in CNS Health and Disease: From Molecular Mechanisms to Therapeutic Opportunities
Adibhatla, R. M., & Hatcher, J. F. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2668 · Cited by 480
Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
de la Monte, S. M. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015037 · Cited by 468
Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation
Villapol, S. (2017) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0554-5 · Cited by 386
PPARγ/RXRα-Induced and CD36-Mediated Microglial Amyloid-β Phagocytosis Results in Cognitive Improvement in Amyloid Precursor Protein/Presenilin 1 Mice
Yamanaka, M., Ishikawa, T., Griep, A., Axt, D., Kummer, M. P., & Heneka, M. T. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1569-12.2012 · Cited by 326
Self-citation
Fish, docosahexaenoic acid and Alzheimer’s disease
Cunnane, S. C., Plourde, M., Pifferi, F., Bégin, M. E., Féart, C., & Barberger‐Gateau, P. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2009.04.001 · Cited by 336
Stress as a neuroinflammatory condition in brain: Damaging and protective mechanisms
García‐Bueno, B., Caso, J. R., & Leza, J. C. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.04.001 · Cited by 291
PPARγ Agonists as Therapeutics for the Treatment of Alzheimer's Disease
Landreth, G. E., Jiang, Q., Mandrekar, S., & Heneka, M. T. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.003 · Cited by 283
Self-citation
Contributions of Brain Insulin Resistance and Deficiency in Amyloid-Related Neurodegeneration in Alzheimerʼs Disease
de la Monte, S. M. (2012) · Drugs · doi:10.2165/11597760-000000000-00000 · Cited by 265
Localization of PPAR isotypes in the adult mouse and human brain
Warden, A. S., Truitt, J., Merriman, M., Ponomareva, O. Y., Jameson, K. G., Ferguson, L. B., Mayfield, R. D., & Harris, R. A. (2016) · Scientific Reports · doi:10.1038/srep27618 · Cited by 243
Marine omega‐3 (n‐3) phospholipids: A comprehensive review of their properties, sources, bioavailability, and relation to brain health
Ahmmed, M. K., Ahmmed, F., Tian, H. S., Carne, A., & Bekhit, A. E. A. (2019) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12510 · Cited by 254
Evidence for impaired amyloid β clearance in Alzheimer's disease
Wildsmith, K. R., Holley, M., Savage, J. C., Skerrett, R., & Landreth, G. E. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt187 · Cited by 249
Self-citation
Inflammatory Aspects of Alzheimer Disease and Other Neurodegenerative Disorders
Schwab, C., & McGeer, P. L. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-13402 · Cited by 235
Stress-induced neuroinflammation: mechanisms and new pharmacological targets
Munhoz, C. D., García‐Bueno, B., Madrigal, J. L. M., Lepsch, L. B., Scavone, C., & Leza, J. C. (2008) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2008001200001 · Cited by 231
Radiation-induced brain injury: current concepts and therapeutic strategies targeting neuroinflammation
Turnquist, C., Harris, B. T., & Harris, C. C. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa057 · Cited by 235
Estradiol or genistein prevent Alzheimer's disease-associated inflammation correlating with an increase PPARγ expression in cultured astrocytes
Valles, S. L., Dolz-Gaiton, P., Gambini, J., Borras, C., LLoret, A., Pallardo, F. V., & Viña, J. (2010) · Brain Research · doi:10.1016/j.brainres.2009.11.044 · Cited by 186
Effect of pioglitazone medication on the incidence of dementia
Heneka, M. T., Fink, A., & Doblhammer, G. (2015) · Annals of Neurology · doi:10.1002/ana.24439 · Cited by 187
Self-citation
Pro-/Anti-inflammatory Dysregulation in Patients With First Episode of Psychosis: Toward an Integrative Inflammatory Hypothesis of Schizophrenia
García‐Bueno, B., Bioque, M., MacDowell, K. S., Barcones, M. F., Martínez‐Cengotitabengoa, M., Pina‐Camacho, L., Rodríguez–Jiménez, R., Sáiz, P. A., Castro, C., Lafuente, A., et al. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt001 · Cited by 180
BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and β-amyloid production in Alzheimer’s disease
Chami, L., & Checler, F. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-52 · Cited by 168
Fatty Acid Signaling Mechanisms in Neural Cells: Fatty Acid Receptors
Falomir‐Lockhart, L. J., Cavazzutti, G. F., Giménez, E., & Toscani, A. M. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00162 · Cited by 164
Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5YAPP+ Cells Through PPARγ Involvement
Scuderi, C., Steardo, L., & Esposito, G. (2014) · Phytotherapy Research · doi:10.1002/ptr.5095 · Cited by 161
Peroxisome proliferator-activated receptors and cancer: challenges and opportunities
Youssef, J., & Badr, M. Z. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01383.x · Cited by 159
Therapeutic Strategies for Treatment of Inflammation-related Depression
Adžić, M., Brkic, Z., Mitić, M., Francija, E., Jovicic, M. J., Radulović, J., & Marić, N. P. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170828163048 · Cited by 162
Interference of pollutants with PPARs: endocrine disruption meets metabolism
Casals‐Casas, C., Feige, J. N., & Desvergne, B. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.207 · Cited by 156
Pioglitazone Adjunctive Therapy for Moderate-to-Severe Major Depressive Disorder: Randomized Double-Blind Placebo-Controlled Trial
Sepanjnia, K., Modabbernia, A., Ashrafi, M., Modabbernia, M.-J., & Akhondzadeh, S. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.58 · Cited by 153
Palmitoylethanolamide in CNS health and disease
Raso, G. M., Russo, R., Calignano, A., & Meli, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.05.006 · Cited by 153
Cinnamic acid activates PPARα to stimulate Lysosomal biogenesis and lower Amyloid plaque pathology in an Alzheimer's disease mouse model
Chandra, S., Roy, A., Jana, M., & Pahan, K. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.12.007 · Cited by 150
Ketogenic diet-induced peroxisome proliferator-activated receptor-γ activation decreases neuroinflammation in the mouse hippocampus after kainic acid-induced seizures
Jeong, E. A., Jeon, B. T., Shin, H. J., Kim, N., Lee, D. H., Kim, H. J., Kang, S. S., Cho, G. J., Choi, W. S., & Roh, G. S. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.09.001 · Cited by 146
PPAR: a therapeutic target in Parkinson’s disease
Chaturvedi, R. K., & Beal, M. F. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05388.x · Cited by 151
Activation of Nuclear PPARγ Receptors by the Antidiabetic Agent Pioglitazone Suppresses Alcohol Drinking and Relapse to Alcohol Seeking
Stopponi, S., Somaini, L., Cippitelli, A., Cannella, N., Braconi, S., Kallupi, M., Ruggeri, B., Heilig, M. A., Demopulos, G. A., Gaitanaris, G., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.010 · Cited by 136
The Endocannabinoid System and PPARs: Focus on Their Signalling Crosstalk, Action and Transcriptional Regulation
Iannotti, F. A., & Vitale, R. M. (2021) · Cells · doi:10.3390/cells10030586 · Cited by 130
Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) and Neurodegenerative Disorders
Chen, Y., Wu, J., Tsai, H.-D., Huang, C., Chen, J.-J., Sun, G. Y., & Lin, T. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8259-8 · Cited by 132
Nuclear receptors as therapeutic targets for Alzheimer's disease
Mandrekar-Colucci, S., & Landreth, G. E. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.594043 · Cited by 126
Self-citation
Rosiglitazone Treatment Prevents Mitochondrial Dysfunction in Mutant Huntingtin-expressing Cells
Quintanilla, R. A., Jin, Y. N., Fuenzalida, K. M., Bronfman, M., & Johnson, G. V. W. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804291200 · Cited by 128
Molecular mechanism of PPAR in the regulation of age-related inflammation
Chung, J. H., Seo, A. Y., Chung, S. W., Kim, M. K., Leeuwenburgh, C., Yu, B. P., & Chung, H. Y. (2008) · Ageing Research Reviews · doi:10.1016/j.arr.2008.01.001 · Cited by 125
PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation
Zolezzi, J. M., Santos, M. J., Candia, S. B., Pinto, C., Godoy, J. A., & Inestrosa, N. C. (2017) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12320 · Cited by 123
Pleiotropic Role of PPAR γ in Intracerebral Hemorrhage: An Intricate System Involving Nrf2, RXR , and NF ‐κB
Zhao, X., Gonzales, N. R., & Aronowski, J. A. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12350 · Cited by 122
Therapeutic journey of 2,4-thiazolidinediones as a versatile scaffold: An insight into structure activity relationship
Naim, M. J., Alam, M. J., Ahmad, S., Nawaz, F., Shrivastava, N., Sahu, M., & Alam, O. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.02.031 · Cited by 119
Polyunsaturated fatty acids and endocannabinoids in health and disease
Freitas, H. R., Isaac, A. R., Malcher‐Lopes, R., Diaz, B. L., Trevenzoli, I. H., & Reis, R. A. D. M. (2017) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1347373 · Cited by 118
Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression
Kashani, L., Omidvar, T., Farazmand, B., Modabbernia, A., Ramzanzadeh, F., Tehraninejad, E. S., Ashrafi, M., Tabrizi, M., & Akhondzadeh, S. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.08.010 · Cited by 116
Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation
MacDowell, K. S., García‐Bueno, B., Madrigal, J. L. M., Parellada, M., Arango, C., Micó, J. A., & Leza, J. C. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001775 · Cited by 115
Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-α
Scuderi, C., Valenza, M., Stecca, C., Esposito, G., Carratù, M. R., & Steardo, L. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-49 · Cited by 112
Icariin attenuates cerebral ischemia–reperfusion injury through inhibition of inflammatory response mediated by NF-κB, PPARα and PPARγ in rats
Xiong, D., Deng, Y., Huang, B., Yin, C., Liu, B., Shi, J., & Gong, Q. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.11.035 · Cited by 103
Role of platelets in neuroinflammation: a wide-angle perspective
Horstman, L. L., Jy, W., Ahn, Y. S., Zivadinov, R., Maghzi, A. H., Etemadifar, M., Alexander, J. S., & Minagar, A. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-10 · Cited by 108
May Diet and Dietary Supplements Improve the Wellness of Multiple Sclerosis Patients? A Molecular Approach
Riccio, P., Rossano, R., & Liuzzi, G. M. (2010) · Autoimmune Diseases · doi:10.4061/2010/249842 · Cited by 105
Synthesis and biological evaluation of novel pyrazolyl-2,4-thiazolidinediones as anti-inflammatory and neuroprotective agents
Youssef, A., White, M. S., Villanueva, E. B., El‐Ashmawy, I. M., & Klegeris, A. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.01.021 · Cited by 103
Effects of Bisphenol-A and Other Endocrine Disruptors Compared With Abnormalities of Schizophrenia: An Endocrine-Disruption Theory of Schizophrenia
Brown, J. S. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm147 · Cited by 102
The PPAR-gamma agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function
Gray, E., Ginty, M., Kemp, K. C., Scolding, N. J., & Wilkins, A. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-63 · Cited by 98
PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease
Barbiero, J. K., Santiago, R. M., Tonin, F. S., Boschen, S. L., da Silva, L. M., Werner, M. F. D. P., Cunha, C. D., Lima, M. M. S., & Vital, M. A. B. F. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.02.009 · Cited by 97
Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer’s Disease and Other Neurodegenerative Diseases
Calsolaro, V., & Edison, P. (2015) · CNS Drugs · doi:10.1007/s40263-015-0301-8 · Cited by 93
Regulation of brain PPARgamma2 contributes to ketogenic diet anti-seizure efficacy
Simeone, T. A., Matthews, S. A., Samson, K. K., & Simeone, K. A. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.08.006 · Cited by 92
Towards Retinoid Therapy for Alzheimers Disease
Shudo, K., Fukasawa, H., Nakagomi, M., & Yamagata, N. (2009) · Current Alzheimer Research · doi:10.2174/156720509788486581 · Cited by 91
The role of polyunsaturated fatty acids and GPR40 receptor in brain
Khan, M. Z., & He, L. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.05.013 · Cited by 92
Anti-apoptotic Actions of PPAR-γ Against Ischemic Stroke
Fong, W.-H., Tsai, H., Chen, Y.-C., Wu, J., & Lin, T. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8103-y · Cited by 87
Microglia and Astrocyte Activation by Toll‐Like Receptor Ligands: Modulation by PPAR‐γ Agonists
Gurley, C. M., Nichols, J. R., Liu, S., Phulwani, N. K., Esen, N., & Kielian, T. (2008) · PPAR Research · doi:10.1155/2008/453120 · Cited by 88
Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses
Aleshin, S. E., Strokin, M., Sergeeva, M. G., & Reiser, G. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.06.012 · Cited by 82
Pharmacological Treatment of Chemotherapy-Induced Neuropathic Pain: PPARγ Agonists as a Promising Tool
Quintão, N. L. M., Santin, J. R., Stoeberl, L. C., Corrêa, T. P., Melato, J., & da Costa, R. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00907 · Cited by 85
Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer’s Disease
Saavedra, J. M. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0327-y · Cited by 84
Fatty Acids, Antioxidants and Physical Activity in Brain Aging
Freitas, H. R., Ferreira, G. C., Trevenzoli, I. H., Oliveira, K. J., & Reis, R. A. D. M. (2017) · Nutrients · doi:10.3390/nu9111263 · Cited by 85
The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia
Martínez‐Gras, I., Perez‐Nievas, B. G., García‐Bueno, B., Madrigal, J. L. M., Andres, E. M., Rodríguez–Jiménez, R., Hoenicka, J., Palomo, T., Rubio, G., & Leza, J. C. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.01.018 · Cited by 80
PPAR agonists regulate brain gene expression: Relationship to their effects on ethanol consumption
Ferguson, L. B., Most, D., Blednov, Y. A., & Harris, R. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.06.024 · Cited by 80
Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice
Dumont, M., Stack, C., Elipenahli, C., Jainuddin, S., Gerges, M., Starkova, N. N., Calingasan, N. Y., Yang, L., Tampellini, D., Starkov, A. A., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds355 · Cited by 78
Assay of vtg, ERs and PPARs as endpoint for the rapid in vitro screening of the harmful effect of Di-(2-ethylhexyl)-phthalate (DEHP) and phthalic acid (PA) in zebrafish primary hepatocyte cultures
Maradonna, F., Evangelisti, M., Gioacchini, G., Migliarini, B., Olivotto, I., & Carnevali, O. (2012) · Toxicology in Vitro · doi:10.1016/j.tiv.2012.09.018 · Cited by 74
Therapeutic potential of nuclear receptor agonists in Alzheimer's disease
Moutinho, M., & Landreth, G. E. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075556 · Cited by 76
Self-citation
Signaling Mechanisms of Selective PPARγ Modulators in Alzheimer’s Disease
Govindarajulu, M., Pinky, P. D., Bloemer, J., Ghanei, N., Suppiramaniam, V. D., & Amin, R. (2018) · PPAR Research · doi:10.1155/2018/2010675 · Cited by 77
Peroxisome proliferator‐activated receptor γ ligands regulate neural stem cell proliferation and differentiation in vitro and in vivo
Morales-Garcia, J. A., Luna‐Medina, R., Alfaro‐Cervelló, C., Cortés‐Canteli, M., Santos, Á., García‐Verdugo, J. M., & Pérez‐Castillo, A. (2010) · Glia · doi:10.1002/glia.21101 · Cited by 72
Peroxisome Proliferator-Activated Receptor (PPAR)-γ Positively Controls and PPARα Negatively Controls Cyclooxygenase-2 Expression in Rat Brain Astrocytes through a Convergence on PPARβ/δ via Mutual Control of PPAR Expression Levels
Aleshin, S. E., Grabeklis, S. A., Hanck, T., Sergeeva, M. G., & Reiser, G. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.056010 · Cited by 72
Cannabidiol Reverses Deficits in Hippocampal LTP in a Model of Alzheimer’s Disease
Hughes, B., & Herron, C. E. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2513-z · Cited by 77
Expression of E‐FABP in PC12 cells increases neurite extension during differentiation: involvement of n‐3 and n‐6 fatty acids
Liu, J., Almaguel, F. G., Bu, L., León, D. D., & León, M. A. D. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05507.x · Cited by 71
Effects and Underlying Mechanisms of Bioactive Compounds on Type 2 Diabetes Mellitus and Alzheimer’s Disease
Li, R., Zhang, Y., Rasool, S., Geetha, T., & Babu, J. R. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8165707 · Cited by 78
Role of the peroxisome proliferator-activated receptors (PPAR)-α, β/δ and γ triad in regulation of reactive oxygen species signaling in brain
Aleshin, S. E., & Reiser, G. (2013) · Biological Chemistry · doi:10.1515/hsz-2013-0215 · Cited by 70
Effects of the PPAR- α Agonist Fenofibrate on Acute and Short-Term Consequences of Brain Ischemia
Ouk, T., Gautier, S., Pétrault, M., Montaigne, D., Maréchal, X., Masse, I., Devedjian, J.-C., Deplanque, D., Bastide, M., Nevière, R., et al. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.233 · Cited by 67
Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study
Lu, C.-H., Yang, C., Li, C., Hsieh, C., & Ou, H. (2017) · Diabetologia · doi:10.1007/s00125-017-4499-5 · Cited by 70
Role of Non-Neuronal Cells in Body Weight and Appetite Control
Argente-Arizón, P., Freire‐Regatillo, A., Argente, J., & Chowen, J. A. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00042 · Cited by 70
Association Between the Use of Antihyperglycemic Drugs and Dementia Risk: A Case-Control Study
Bohlken, J., Jacob, L., & Kostev, K. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180808 · Cited by 67
Plant derived omega-3-fatty acids protect mitochondrial function in the brain
Eckert, G. P., Franke, C., Nöldner, M., Rau, O., Wurglics, M., Schubert‐Zsilavecz, M., & Müller, W. E. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.01.005 · Cited by 67
Neuroinflammation in Alzheimer's disease: an understanding of physiology and pathology
Obulesu, M., & Jhansilakshmi, M. (2013) · International Journal of Neuroscience · doi:10.3109/00207454.2013.831852 · Cited by 66
Gemfibrozil, a Lipid-Lowering Drug, Lowers Amyloid Plaque Pathology and Enhances Memory in a Mouse Model of Alzheimer’s Disease via Peroxisome Proliferator-Activated Receptor α
Chandra, S., & Pahan, K. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190104 · Cited by 68
PPAR-Alpha Agonists as Novel Antiepileptic Drugs: Preclinical Findings
Puligheddu, M., Pillolla, G., Melis, M., Lecca, S., Marrosu, F., Demontis, M., Scheggi, S., Carta, G., Murru, E., Aroni, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064541 · Cited by 61
Brain histological changes in young mice submitted to diets with different ratios of n-6/n-3 polyunsaturated fatty acids during maternal pregnancy and lactation
Tian, C., Fan, C., Liu, X., Xu, F., & Qi, K. (2011) · Clinical Nutrition · doi:10.1016/j.clnu.2011.03.002 · Cited by 65
Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor
García, C., Gómez‐Cañas, M., Burgaz, S., Palomares, B., Gómez‐Gálvez, Y., Palomo‐Garo, C., Campo, S., Ferrer-Hernández, J., Pavicic, C., Navarrete, C. M., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1060-5 · Cited by 65
The role of astrocytes in the hypothalamic response and adaptation to metabolic signals
Chowen, J. A., Argente-Arizón, P., Freire‐Regatillo, A., Frago, L. M., Horváth, T. L., & Argente, J. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.001 · Cited by 68
Strategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease
Haas, C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110986 · Cited by 61
PPARγ and Cognitive Performance
d’Angelo, M., Castelli, V., Catanesi, M., Antonosante, A., Dominguez-Benot, R., Ippoliti, R., Benedetti, E., & Cimini, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205068 · Cited by 63
Peroxisome proliferator-activated receptor-α activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: Possible neuroprotective mechanisms
Bhateja, D., Dhull, D. K., Gill, A., Sidhu, A., Sharma, S., Reddy, B. V. K., & Padi, S. S. V. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.10.029 · Cited by 60
PPARγ transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons
Du, J., Zhang, L., Liu, S., Zhang, C., Huang, X., Li, J., Zhao, N., & Wang, Z. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.04.047 · Cited by 60
Fenofibrate, a peroxisome proliferator–activated receptor‐α agonist, exerts anticonvulsive properties
Porta, N., Vallée, L., Lecointe, C., Bouchaert, E., Staels, B., Bordet, R., & Auvin, S. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01901.x · Cited by 60
Inflammation and the Redox‐sensitive AGE–RAGE Pathway as a Therapeutic Target in Alzheimer's Disease
Maczurek, A. E., Shanmugam, K., & Münch, G. W. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1433.026 · Cited by 60
Treatment of rats with pioglitazone in the reperfusion phase of focal cerebral ischemia: A preclinical stroke trial
Čulman, J., Nguyen-Ngoc, M., Glatz, T., Gohlke, P., Herdegen, T., & Zhao, Y. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.09.003 · Cited by 59
Role of Nuclear Receptors in Central Nervous System Development and Associated Diseases
Maria, A. A., Moreno-Ramos, O. A., & Haider, N. B. (2015) · Journal of Experimental Neuroscience · doi:10.4137/jen.s25480 · Cited by 63
Neuroprotective effect of PPAR alpha and gamma agonists in a mouse model of amyloidogenesis through modulation of the Wnt/beta catenin pathway via targeting alpha- and beta-secretases
Assaf, N., El-Shamarka, M. E.-S., Salem, N. A., Khadrawy, Y. A., & Sayed, N. S. E. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109793 · Cited by 58
Regulation of peroxisome proliferator‐activated receptors (PPAR) α and ‐γ of rat brain astrocytes in the course of activation by toll‐like receptor agonists
Chistyakov, D. V., Aleshin, S. E., Astakhova, A. A., Sergeeva, M. G., & Reiser, G. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13101 · Cited by 58
Bezafibrate, a Peroxisome Proliferator-Activated Receptors Agonist, Decreases Body Temperature and Enhances Electroencephalogram Delta-Oscillation during Sleep in Mice
Chikahisa, S., Tominaga, K., Kawai, T., Kitaoka, K., Oishi, K., Ishida, N., Rokutan, K., & Séi, H. (2008) · Endocrinology · doi:10.1210/en.2008-0285 · Cited by 57
INFERNO: inferring the molecular mechanisms of noncoding genetic variants
Amlie‐Wolf, A., Tang, M., Mlynarski, E. E., Kuksa, P. P., Valladares, O., Katanić, Ž., Tsuang, D. W., Brown, C. D., Schellenberg, G. D., & Wang, L. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky686 · Cited by 56
Therapeutic targets of brain insulin resistance in sporadic Alzheimer s disease
de la Monte, S. M. (2012) · Frontiers in Bioscience-Elite · doi:10.2741/e482 · Cited by 57
Elucidating the Neuroprotective Role of PPARs in Parkinson’s Disease: A Neoteric and Prospective Target
Behl, T., Madaan, P., Sehgal, A., Singh, S., Sharma, N., Bhatia, S., Al‐Harrasi, A., Chigurupati, S., Alrashdi, I., & BUNGAU, S. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810161 · Cited by 58
PPAR-γ Agonist Azelaoyl PAF Increases Frataxin Protein and mRNA Expression. New Implications for the Friedreich’s Ataxia Therapy
Marmolino, D., Acquaviva, F., Pinelli, M., Monticelli, A., Castaldo, I., Filla, A., & Cocozza, S. (2008) · The Cerebellum · doi:10.1007/s12311-008-0087-z · Cited by 59
The Peroxisome Proliferator-activated Receptor γ (PPARγ) Controls Natural Protective Mechanisms against Lipid Peroxidation in Amyotrophic Lateral Sclerosis
Benedusi, V., Martorana, F., Brambilla, L., Maggi, A. C., & Rossi, D. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.366419 · Cited by 58

Authors: HENEKA, M., & LANDRETH, G.
Affiliations: University of Münster (DE)
Case Western Reserve University (US)
Corresponding author: HENEKA, M
ORCID: HENEKA, M
LANDRETH, G
Venue: Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Publisher: Elsevier BV
Published: 2007-08
Volume: 1771
Issue: 8
Pages: 1031-1045
ISSN: 1388-1981 (ISSN-L)
DOI: 10.1016/j.bbalip.2007.04.016
OpenAlex: W2054685711
Cited by: 317
References: 181
Citations by year: 2026: 4 · 2025: 13 · 2024: 16 · 2023: 11 · 2022: 12 · 2021: 12 · 2020: 10 · 2019: 20 · 2018: 13 · 2017: 20 · 2016: 17 · 2015: 16 · 2014: 21 · 2013: 18 · 2012: 21
FWCI: 9.13
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids (publishedVersion)
PubMed (publishedVersion)
Open Repository and Bibliography (University of Luxembourg) (submittedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords: peroxisome proliferator-activated receptors, PPARγ, brain, neuroinflammation, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, neurodegeneration, amyloid-beta, nonsteroidal anti-inflammatory drugs, PPAR agonists, neuroprotection, central nervous system development
MeSH terms: Animals, Brain, Brain Neoplasms, Central Nervous System Diseases, Brain Ischemia, Encephalomyelitis, Autoimmune, Experimental, Humans, Neurodegenerative Diseases, Peroxisome Proliferator-Activated Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PPARs in the brain

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks